> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Latest Federal Register Notices
- URL: https://www.fdaweb.com/latest-federal-register-notices-180/
- Published: 2018-05-20T12:00:00.000Z
- Updated: 2026-09-15T00:06:16.000Z
- Author: David McFarland
- Tags: FDA Policy/General, #legacy-id-D5141482

[**Blood Establishment Software Put Into Class 2**](https://www.fdaweb.com/blood-establishment-software-put-into-class-2/)  
*Federal Register* final rule: FDA classifies blood establishment computer software and accessories (regulated under product code MMH) into Class 2 (special controls). 05/18/2018

[**Panel to Review PneumRx PMA for Elevair Endobronchial Coil System**](https://www.fdaweb.com/panel-to-review-pneumrx-pma-for-elevair-endobronchial-coil-system/)  
*Federal Register* notice: FDA announces a 6/14 Anesthesiology and Respiratory Therapy Devices Panel of the Medical Devices Advisory Committee meeting to review a PneumRx PMA for the PneumRx Elevair Endobronchial Coil System. 05/17/2018

[**OMB Approves 6 Info Collection Requests**](https://www.fdaweb.com/omb-approves-6-info-collection-requests/)  
*Federal Register* notice: FDA posts a list of recent information collections that have been approved by OMB. 05/16/2018

[**Blood Products Panel to Meet in July**](https://www.fdaweb.com/blood-products-panel-to-meet-in-july/)  
*Federal Register* notice: FDA announces a 7/18-19 Blood Products Advisory Committee. 05/16/2018

[**Proposed Rule to Update Combo Product Regulations**](https://www.fdaweb.com/proposed-rule-to-update-combo-product-regulations/)  
*Federal Register* proposed rule: FDA proposes to amend its regulations concerning the classification of products as biologics, devices, drugs, or combination products, and their assignment to agency components for premarket review and regulation. 05/15/2018

[**Public Meeting on Chronic Pain Patient Input**](https://www.fdaweb.com/public-meeting-on-chronic-pain-patient-input/)  
*Federal Register* notice: FDA announces a 7/9 public meeting on “Patient-Focused Drug Development for Chronic Pain” that is intended to provide patients with an opportunity to present their perspectives on the impacts of chronic pain. 05/15/2018

[**Pediatric Oncology Drugs Advisory Committee Meeting 6/20**](https://www.fdaweb.com/pediatric-oncology-drugs-advisory-committee-meeting-6-20/)  
*Federal Register* notice: FDA announces a Pediatric Oncology Subcommittee of the Oncologic Drugs Advisory Committee meeting 6/20 to review and discuss a list of molecular targets for product development. 05/15/2018

[**Draft Guide on Pediatric HIV Studies**](https://www.fdaweb.com/draft-guide-on-pediatric-hiv-studies/)  
*Federal Register* notice: FDA makes available a draft entitled “Pediatric HIV Infection: Drug Development for Treatment.” 05/14/2018

[**Info Collection on Drug Supply Chain Security Pilot**](https://www.fdaweb.com/info-collection-on-drug-supply-chain-security-pilot/)  
*Federal Register* notice: FDA submits for OMB approval a new proposed information collection entitled “DSCSA Pilot Project Program.” 05/14/2018

[**FDA Partial Withdrawal of OTC Monograph**](https://www.fdaweb.com/fda-partial-withdrawal-of-otc-monograph/)  
*Federal Register* notice: FDA announces a partial withdrawal of a proposed rule published in the 8/21/2003 Federal Register that would have amended the agency’s tentative final monograph for over-the-counter internal analgesic, antipyretic, and antirheumatic drug products to include ibuprofen as generally recognized as safe and effective. 05/14/2018